News Corporate Actions Rekvina Laboratories Limited Schedules Board Meeting for March 16, 2026 to Consider Preferential Equity IssueRekvina Laboratories Limited Schedules Board Meeting for March 16, 2026 to Consider Preferential Equity Issue
Rekvina Laboratories Limited has scheduled a board meeting for March 16, 2026, to consider and approve a preferential issue of equity shares under SEBI ICDR Regulations 2018. The company has implemented a trading window closure for all connected persons until 48 hours after the meeting concludes. The proposal is subject to requisite regulatory approvals and represents a significant capital raising initiative for the pharmaceutical company.
*this image is generated using AI for illustrative purposes only.
Rekvina Laboratories Limited has announced that its board of directors will convene on March 16, 2026, to deliberate on a significant corporate proposal involving the preferential issue of equity shares. The pharmaceutical company informed BSE Limited about this scheduled meeting through a regulatory filing dated March 11, 2026.
Board Meeting Agenda
The primary focus of the upcoming board meeting will be to consider, evaluate, and potentially approve a proposal for issuing equity shares or other securities through a preferential route. This proposed issuance will be conducted in strict accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended.
| Meeting Details: | Information |
|---|---|
| Date: | March 16, 2026 |
| Day: | Monday |
| Purpose: | Preferential issue of equity shares |
| Regulatory Framework: | SEBI ICDR Regulations 2018 |
The company has clarified that any final approval will be subject to obtaining requisite consents and approvals as applicable under the regulatory framework.
Trading Window Restrictions
In compliance with insider trading prevention measures, Rekvina Laboratories has implemented a trading window closure effective immediately. This restriction applies to all connected persons, officers, designated employees, insiders, directors, and their immediate relatives.
The trading window will remain closed until 48 hours after the conclusion of the board meeting on March 16, 2026. This measure aligns with the company's code of conduct for prevention of insider trading, which is framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended.
Company Information
The announcement was signed by Amit Mukesh Shah, Managing Director of Rekvina Laboratories Limited, bearing DIN 01993211. The company operates under CIN L24231GJ1988PLC01145 and maintains its registered office at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda.
This board meeting represents a significant corporate development for the pharmaceutical company as it explores capital raising opportunities through preferential equity issuance, subject to board approval and regulatory compliance.
18
